共 5 条
[1]
Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study （ECASS II）[J] . Vincent Larrue,Rüdiger von Kummer,Achim Müller,Erich Bluhmki.Stroke: Journal of the American Heart Association . 2001 (2)
[2]
Trials of streptokinase in severe acute ischaemic stroke[J] . Eyal Shahar,PaulG. McGovern,Marc Hommel,Jean Pierre Boissel,GeoffreyA. Donnan,StephenM. Davis,BrianR. Chambers,PeterC. Gates,GraemeJ. Hankey,JohnJ. McNeil,David Rosen,EdwardG. Stewart-Wynne,RogerR. Tuck.The Lancet . 1995 (8949)
[3]
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke[J] . Multicentre Acute Stroke Trial—Italy （MAST-I） Group.The Lancet . 1995 (8989)
[4]
FACTORS RELATED TO INTRACRANIAL HEMATOMA FORMATION IN PATIENTS RECEIVING TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOR ACUTE ISCHEMIC STROKE
[J].
STROKE,
1994, 25 (02)
:291-297
LEVY, DE
;
BROTT, TG
;
HALEY, EC
;
MARLER, JR
;
SHEPPARD, GL
;
BARSAN, W
;
BRODERICK, JP
.
[5]
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator （r-TPA）[J] . H. Zeumer,H. -J. Freitag,F. Zanella,A. Thie,C. Arning.Neuroradiology . 1993 (2)